Appendix 4C Revised
| Stock | Bioxyne Ltd (BXN.ASX) |
|---|---|
| Release Time | 28 Jan 2026, 8:35 a.m. |
| Price Sensitive | Yes |
Bioxyne Ltd reports record quarterly revenue and cash receipts
- Record $17.2 million quarterly revenue, a 112% increase on Q2 FY25
- Record $18.4 million quarterly Cash Receipts, a 149% increase on Q2 FY25
- $2.5 million positive Q2 cash flow from operating activities
Bioxyne Ltd (ASX: BXN), an Australian pharmaceutical company focused on the development and commercialisation of innovative medicines and active pharmaceutical ingredients, has reported a strong Q2 FY26 trading performance. The company recorded record quarterly revenue of $17.2 million, a 21% increase on the previous quarter, and record quarterly cash receipts of $18.4 million, a 149% increase on Q2 FY25. The revenue growth was driven by sustained demand for Breathe Life Sciences (BLS) Australia's cannabis portfolio, including flower, oils, vapes, pastilles, and the newly launched Que Medical Inhalation Device. International expansion also contributed significantly, with additional invoicing from German purchase orders, the Curaleaf partnership, and MDMA supplies. The psychedelics segment emerged as a growth driver with the release and shipment of MDMA capsules. The company reported positive operating cash flow of $2.5 million for the quarter and ended the period with $7.6 million in cash. Bioxyne also made several operational achievements during the quarter, including a dual listing on the Frankfurt Stock Exchange, an exclusive agreement with Curaleaf International, and the manufacture and supply of Australia's first domestically produced GMP-compliant MDMA capsules. The company also secured funding to establish a new GMP manufacturing facility in the Scottish Borders and was recognized in the Deloitte Technology Fast 50 Australia 2025 awards.
The company is guiding for FY2026 revenue of $65-75 million and underlying EBITDA of $11.5-13.5 million.
Bioxyne is focused on executing its international expansion plans, including the UK GMP facility fit-out and Central American market entry, improving operational efficiencies, gaining EU GMP certification in Europe, and expanding its medicinal cannabis and psychedelics sales in core markets with local partners.